RxDoctor Payments Data

Sanjay Reddy, MD

Surgery · Philadelphia, PANPI 1548585284

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,720 of the $1,983 with a category attached, or 86.8%. Intuitive Surgical accounts for 89.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $1,787 and has fallen 97.6% since, to $43 in 2025.

$1,983in general payments, 2019–2025

Across 13 payments — averaging $152.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AbbVie$125
  • Daiichi Sankyo Inc.$28
  • Aimmune Therapeutics, Inc.$15
  • Digestive Care, Inc.$14
  • TELA Bio, Inc.$14
  • plus $13 from 1 others
$22,600in research payments, 2019–2025

Across 2 payments — averaging $11,300 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$23K

What the payments were for

  • Travel & lodging$1,72087%
  • Food & beverage$26313%

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,983 in reported general payments places this provider in the 60th percentile of 1,424 surgery providers in Pennsylvania.

See all surgery providers in Pennsylvania →

Medicare billing

Part B allowed, 2024
$136,752
Medicare patients
406
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase24$78,909
Pantoprazole Sodium42$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$125$78,90924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,424 surgery providers in Pennsylvania.

Other surgery in Philadelphia

See the full list for Pennsylvania →

Where these figures come from

Is this you, or does something look wrong? →